drugset / Trial / NCT00512083
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The overall aim of this study is to assess the efficacy and safety of AS1411, over a range of doses, when combined with cytarabine, in the treatment of patients with primary refractory or relapsed acute myeloid leukemia (AML).
Timeline
- Start
- 2007-07
- Primary completion
- 2009-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AS1411 | Aptamer | 10 mg/kg | Intravenous |
| Subject | AS1411 | Aptamer | 40 mg/kg | Intravenous |